November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced ...
October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today ...
Brian Stamper, VP Cell Therapy Operations will participate in the Endpoints webinar titled “Overcoming Manufacturing Challenges for Advanced Medicines” on November 1st from 12-1pm EST. Click here to register: https://webinars.endpts.com/overcoming-manufacturing-challenges-for-advanced-medicines/ ...
Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs September 06, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), ...
Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma -Top line data expected in second half of ...
https://biobuzz.io/brian-stamper-appointed-vice-president-cell-therapy-operations-at-immunomic-therapeutics/
June 07, 2022 10:24 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic ...
Claire Rosean, Senior Scientist discusses ITI-3000, First-In-Human Trial for Merkel Cell Carcinoma and the preclinical data presented at AACR. Click below to watch the full interview: https://www.oncologytube.com/video/40935/claire-rosean-phd-immunomix-uw-aacr22-mcc-iti-3000-first-in-human-trial?channelName=AACR
April 14, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that ...
Both DNA Cancer Vaccines Studied Were Derived from Immunomic’s UNITE™ Platform Phase 1 Study of MCPyV-LT Vaccine in Merkel Cell Carcinoma to Begin in Q2 April 08, 2022 01:15 PM Eastern ...
March 31, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that ...
February 11, 2022 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today ...